ZVRA
Zevra Therapeutics Inc.
NASDAQ: ZVRA · HEALTHCARE · BIOTECHNOLOGY
$10.17
+5.17% today
Updated 2026-04-30
Market cap
$585.24M
P/E ratio
7.33
P/S ratio
5.50x
EPS (TTM)
$1.35
Dividend yield
—
52W range
$7 – $13
Volume
1.1M
Zevra Therapeutics Inc. (ZVRA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-4.43M | $-4.33M | $-14.67M | $-20.27M | $-29.77M | $-33.10M | $-54.20M | $-23.74M | $-1.94M | $10.44M | $-18.72M | $-33.53M | $-69.67M | $-1.60M |
| Capital expenditures | $18943.00 | $51000.00 | $48723.00 | $135000.00 | $643000.00 | $181000.00 | $21000.00 | $26000.00 | $33000.00 | $102000.00 | $93000.00 | $296000.00 | $0.00 | $835000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $467991.00 | $134000.00 | $213758.00 | $2.37M | $6.60M | $4.56M | $6.50M | $4.41M | $2.49M | $2.44M | $4.29M | $5.95M | $14.91M | $12.63M |
| Free cash flow | $-4.45M | $-4.38M | $-14.72M | $-20.40M | $-30.41M | $-33.28M | $-54.22M | $-23.76M | $-1.97M | $10.34M | $-18.81M | $-33.83M | $-69.67M | $-2.43M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | $30.82M | $324000.00 | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — |